Testing dostarlimab with short radiation for MSI rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your rectal cancer is stage II or III and located in the middle or lower part of the rectum
- Your tumor has been tested and shows high microsatellite instability (MSI-H) or a mismatch repair deficiency (dMMR)
- You are in good overall health (able to do daily activities and have normal blood cell counts, liver, and kidney function)
- You have not had prior immunotherapy, chemotherapy, or radiation for rectal cancer
- You do not have a serious autoimmune disease, active infection, or other condition that would make treatment risky
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This study tests how long treatment with a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) should continue in people with a certain type of rectal cancer. The goal is to see if treatment can be shortened based on how well the tumor responds, which may mean fewer side effects and a quicker recovery.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
Hear when a new Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.